VTE elevated risk is assoc up to 1 yr after high disease activity in RA 1% over 1 yr of active RA will get VTE OP0034 Data from Swedish popn study implications irrespective for which Rx pt gets? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR20 #eular2020 https://t.co/A7mWoYZI9S

VTE are LESS in RA using TNFi vs csDMARDs and other bDMARDs from German large RABBIT registry. No JAKi in this analysis. HOT TOPIC. Also may be true for Crohns @eular_org #EULAR2020goesvirtual #eular20 @RheumNow @CRASCRRheum opening plenary https://t.co/RQVbY4ztGt

RA pts are at risk of pneumonia, & inflamed lung mucosa can produce RF/CCP. Are these linked via subclinical lung injury? Seropos RA pts @BrighamWomens have double the pneumonia risk post-adjustment. We're still learning more about RF... @jeffsparks OP0111 #EULAR2020 @RheumNow https://t.co/C3CYpXABGc

GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail. Large Israeli database says there are links (EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why? OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah

AAV/PAN and cancer: risk from meds has always been the question. Interesting therefore that GPA/MPA pts accumulated incident cancer risk over time, whereas other AAV/PAN pts had risk early after dx... Jo Tieu 🇦🇺@earlyARA @helenkeen73 @CatherineL_Hill OP0145 #EULAR2020 @RheumNow https://t.co/8ywycZuMHV

Tenosynovitis is underrated in RA. A nice reminder from an Argentinian group, who USS scanned 90 RA pts in clinical remission >3m and followed them for 12m. Subclinical synovitis did not predict flares, but subclinical tenosynovitis did (adj OR 9.8) THU0119 #EULAR2020 @RheumNow https://t.co/kcle8qyQbI

Physician global assessment in RA is a murky beast, which we should standardise better (especially interrater). Portuguese cross-sectional (n = 392): SJC/CRP/HAQ/PGA did not fully explain it. What are we capturing, and does it matter? THU0111 #EULAR2020 @Janetbirdope @RheumNow https://t.co/krL2yFIl8a

Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing). It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab! @DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd

JAKi and VTE from @WHO VigiBase @UMCGlobalSafety Why the difference between Europe and US? There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM

RA isn't just a disease of joints & tendons: muscle is abnormal even at diagnosis. Changes throughout disease seen on MRI: T2, fatty infiltration, muscle volume all vary at different stages. Plenty more to understand/optimise! @LeedsBRC @DrAiLynTan OP0332 #EULAR2020 @RheumNow https://t.co/PwjLuZ1wcL https://t.co/QSYZALfi29

• Muscle Deterioration due to Rheumatoid Arthritis

I mean, the EULAR recommendations for management of early arthritis are tough: "1. Patients presenting arthritis... should be referred to, and seen by, a rheumatologist, within 6 weeks after the onset of symptoms" Does it matter though? https://t.co/wJkVHQZqjs

• https://twitter.com/drdavidliew/status/1268830312869400576?s=20

Outcome measures => Validity and reliability from @sofiaramiro82 #EULAR2020 @RheumNow https://t.co/M3XIDsTK39

MAINRITSAN3 RCT, RTX v PLBO in AAV 28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8) 1. Selected grp (all pts from MAINRITSAN2) 2. All pts had GC q3mos - IRL benefit could be bigger? Strong data for RTX >2yrs in AAV PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0

• Articles I Have Tweeted About - Organized by Date - Google Drive

Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N

• https://twitter.com/philipcrobinson/status/1268368761838424064

Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa

• EULAR Abstract Archive